STRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Sutro Biopharma Inc (STRO) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong technical indicators, positive analyst sentiment, and improving financial performance. Despite the lack of recent news or significant trading trends, the company's platform potential and clinical developments make it a promising long-term investment.
The technical indicators are bullish. The MACD histogram is positive and expanding, indicating upward momentum. The RSI is at 79.556, which is in the neutral zone but approaching overbought territory. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the current price of $20.47 is above the pivot level of $18.087, with resistance levels at $20.066 and $21.288.
Analysts have upgraded the stock with increased price targets, citing the company's platform potential and clinical developments.
Financials show revenue growth (+13.77% YoY) and improved net income (+16.54% YoY).
The company's STRO-004 program and dual payload antibody-drug conjugates are progressing, indicating strong pipeline potential.
Lack of recent news or significant trading trends from hedge funds or insiders.
The company is still operating at a net loss (-$56.86M in Q3 2025), though improving.
In Q3 2025, Sutro Biopharma's revenue increased by 13.77% YoY to $9.69M. Net income improved by 16.54% YoY to -$56.86M, and EPS increased by 12.61% YoY to -6.7. Gross margin remained at 100%. The financials indicate growth in revenue and narrowing losses, which is a positive sign for long-term investors.
Analysts are optimistic about Sutro Biopharma. Citizens upgraded the stock to Outperform with a $23 price target, citing its platform and clinical progress. Deutsche Bank raised the price target significantly from $5 to $51, maintaining a Buy rating. The focus on STRO-004 and the company's dual payload antibody-drug conjugates highlights strong potential for future growth.
